HMG20A was identified as a key enhancer driver associated with DNA damage repair in oral squamous cell carcinomas

Li Na1, Zhang Meijie2, Zhai Wenjing3

  • 1Department of Stomatology, Second Hospital of Shijiazhuang, 050000, Shijiazhuang, Hebei, China.

BMC Oral Health
|November 6, 2022
PubMed
Abstract

Insights

High mobility group 20A (HMG20A) drives DNA repair in oral squamous cell carcinoma (OSCC) and promotes metastasis. Targeting HMG20A may improve oral cancer treatment by enhancing chemotherapy sensitivity and reducing tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oral squamous cell carcinoma (OSCC) is a prevalent oral cancer subtype.
  • Targeting DNA repair mechanisms is a promising strategy to enhance cancer treatment efficacy.
  • This study investigates key enhancer drivers of DNA damage repair in OSCC.

Purpose of the Study:

  • To identify enhancer drivers regulating DNA damage repair in OSCC.
  • To explore the association between DNA repair gene expression and OSCC clinical phenotypes.
  • To evaluate the therapeutic potential of identified enhancer drivers.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) database for Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA).
  • Identified and visualized enhancers using HOMER and Integrative Genomics Viewer.
  • Predicted transcription factors using Cistrome Data Browser and validated their role via qRT-PCR, ChIP-qPCR, and functional assays.

Main Results:

  • High expression of DNA repair genes correlated with poorer prognosis, advanced stage, and adverse clinical factors in OSCC patients.
  • Seventeen metastasis-specific enhancer-controlled genes were identified, including ADRM1 and SLC12A7.
  • High mobility group 20A (HMG20A) was identified as a key prognostic enhancer driver, promoting metastasis-specific DNA repair gene expression.

Conclusions:

  • HMG20A acts as a crucial prognostic enhancer driver in OSCC, regulating DNA repair.
  • HMG20A promotes OSCC cell proliferation, invasion, and DNA repair, while its inhibition enhances cisplatin sensitivity.
  • HMG20A represents a potential therapeutic target for improving OSCC treatment outcomes.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.1K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.7K
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
3.7K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
DNA Helicases00:55

DNA Helicases

DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
22.0K